Oragenics, Inc. (OGEN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Oragenics, Inc. on November 20, 2020. The company is incorporated in Florida and its common stock trades on the NYSE American under the symbol "OGEN". The report addresses a specific corporate event occurring on the filing date.
Key Financial Metrics
The filing discloses a capital raising event but does not provide comprehensive financial statements, revenue, profit, cash flow, or margin data for the period.
- Capital Raised: $5.25 million via a common stock offering.
- Debt and Liquidity: The filing text does not provide specific values for existing debt, cash balances, or liquidity ratios.
Material Changes
The primary material change reported is the pricing of a $5.25 million common stock offering on November 20, 2020. This represents an increase in the company's equity capital. No other material changes to operations or financial position are detailed in this specific filing.
Guidance, Outlook, and Risks
This 8-K filing serves to announce the stock offering and does not contain management commentary, forward-looking guidance, or a discussion of risks and contingencies. The full details of the offering are referenced in the attached press release (Exhibit 99.1), which is not included in the provided text.
Investor Verification Checklist
- Verify the number of shares issued and the price per share in the attached press release (Exhibit 99.1) to confirm the $5.25 million total.
- Review the company's most recent 10-K or 10-Q to assess current cash balances and liquidity needs prior to this offering.
- Confirm the intended use of proceeds from the $5.25 million offering as detailed in the press release.
- Check for any underwriting agreements or lock-up provisions associated with the offering.